logo-loader
viewLexaria Bioscience Corp

Lexaria Bioscience picks up patents in the US and Australia for its DehydraTECH technology

The patents, two in the US and two in Australia, bring Lexaria’s total to 15 granted patents, along with 60 pending applications around the world

patent stamp
The new patents specifically relate to methods of creating orally-ingestible, fat-soluble agents that can be infused into food or beverages

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the biotechnology company behind the drug delivery system DehydraTECH, announced Thursday that its subsidiary Poviva Corp had been awarded four patents. 

The patents, two in the US and two in Australia, bring Lexaria’s total to 15 granted patents, along with 60 pending applications around the world. 

Collectively, the patents focus on the effective delivery to the body of cannabinoids, anti-inflammatory drugs, nicotine and vitamins.

READ: Lexaria Bioscience taps a former Altria Group executive to join its board of directors

The new patents specifically relate to methods of creating orally-ingestible, fat-soluble agents that can be infused into food or beverages. The idea is to create a result that can dissolve in fat, rather than water 

Separately, Lexaria announced it was issuing 550,000 incentive stock options to employees and consultants of the company, as well as one director. The options are exercisable at a price of US$0.81 per share.

Lexaria stock closed at US$0.80 on Thursday.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp

Price: 0.6 CAD

CSE:LXX
Market: CSE
Market Cap: $47.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Market conditions worsen for cannabis companies but Canntab...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada sank 3.7% to 141.07 points. The OTCQX Cannabis Index slipped 2.6% to 515.3 points. Buds today were Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF), Lexaria Bioscience Corp (CSE:LXX)...

on 10/08/2019

2 min read